GlycoT Therapeutics was awarded a Phase I SBIR
GlycoT was awarded a Phase I SBIR titled “Development of a facile, robust, scalable, and versatile chemoenzymatic glycan-remodeling approach for site-specific antibody conjugation” (1/R43GM146537) with total funding support of $321,239.
Read the full article at: www.glycot.com
- About the Author
- Latest Posts
Over the past 11 years, Chris has grown BioBuzz into a respected brand that is recognized for its community building, networking events and news stories about the local biotech industry. In addition, he runs a Recruiting and Marketing Agency that helps companies attract top talent through a blended model that combines employer branding and marketing services together with a high powered recruiting solution.
